U.S. markets closed
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow 30

    31,500.68
    +823.32 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.43 (+3.34%)
     
  • Russell 2000

    1,765.74
    +54.06 (+3.16%)
     
  • Crude Oil

    107.06
    +2.79 (+2.68%)
     
  • Gold

    1,828.10
    -1.70 (-0.09%)
     
  • Silver

    21.13
    +0.09 (+0.42%)
     
  • EUR/USD

    1.0559
    +0.0034 (+0.33%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.07%)
     
  • USD/JPY

    135.2100
    +0.2770 (+0.21%)
     
  • BTC-USD

    21,369.08
    +322.45 (+1.53%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,491.97
    +320.72 (+1.23%)
     

Sorrento's COVID-19 Main Protease Inhibitor Neutralizes Omicron

·1 min read

Sorrento Therapeutics Inc's (NASDAQ: SRNE) late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits omicron virus entry and replication in cell-based assays.

  • In VeroE6 cells challenged with omicron variant, STI-1558 alone (without efflux inhibitor) showed significant antiviral activity with an EC50 value of 360 nM, equivalent to that seen against the Delta variant (EC50 value, 370 nM).

  • Related: Sorrento Therapeutics' COVID-19 Antibody Works Against Omicron Variant.

  • In an omicron S protein-mediated pseudovirus entry assay, STI-1558 effectively inhibited pseudovirus entry into cells, whereas EUA-approved Pfizer Inc's (NYSE: PFE) nirmatrelvir (Paxlovid) showed no inhibition.

  • STI-1558 showed improved human liver metabolic stability compared to nirmatrelvir, and its oral bioavailability does not depend on the ritonavir co-administration.

  • Without the need to co-administer Ritonavir, STI-1558 potentially avoids significant adverse drug-drug interactions.

  • Price Action: SRNE shares are down 0.35% at $2.87 during the market session on the last check Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.